Compugen Posts $10K in Q4 Revenue; Cash Burn May Require Infusion in Mid-'09 | GenomeWeb
NEW YORK (GenomeWeb News) — Compugen today reported revenue for the fourth quarter as R&D spending increased 20 percent and net loss widened 12 percent.
 
Total receipts for the three months ended Dec. 31, 2006, were $10,000 compared with zero revenue one year ago.
 
Compugen said R&D spending in the quarter rose to $2.9 million from $2.4 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.